Shengtai Pharmaceutical Schedules Fiscal Year 2009 Financial Results and Conference Call
September 28 2009 - 7:00AM
PR Newswire (US)
WEIFANG, China, Sept. 28 /PRNewswire-Asia-FirstCall/ -- Shengtai
Pharmaceutical, Inc. (OTC:SGTI) (BULLETIN BOARD: SGTI) ("Shengtai"
or "the Company"), a leading manufacturer and distributor of
high-quality, pharmaceutical grade glucose products in China, today
announced that it will issue financial results for the fiscal year
ended June 30, 2009 after the close of the stock market on Monday,
September 28, 2009. Management will conduct a conference call on
Tuesday, September 29, 2009 at 9:00 A.M. Eastern Daylight Time to
discuss these results. A question and answer session will follow
management's presentation. Ms. Yiru Melody Shi (CFO), and Ms.
Haining Michelle Wang (Investor Relations Manager) will be the
primary speakers on the call. To participate, please call the
following numbers ten minutes before the call start time: Phone
Number + 1 (877) 407-8035 (North America) Phone Number + 1 (201)
689-8035 (International) A replay of the call will be available
through Tuesday, October 6, 2009, at 11:59 P.M. Eastern Daylight
Time. For the replay, please call: Phone Number +1 (877) 660-6853
(North America) Phone Number +1 (201) 612-7415 (International)
Account Number: 286 Conference ID Number: 333940 About Shengtai
Pharmaceutical, Inc. Shengtai Pharmaceutical, Inc. through its
wholly owned subsidiary, Shengtai Holding, Inc. (SHI), and the
Chinese operating company of Weifang Shengtai Pharmaceutical Co.,
Ltd., is a leading manufacturer and supplier of pharmaceutical
grade glucose used for medical purposes. It also manufactures and
supplies glucose and cornstarch products to the food, beverage and
industrial production industries in China. For more information
about Shengtai Pharmaceutical, Inc., please visit
http://www.shengtaipharmaceutical.com/ . Forward Looking Statements
Certain statements in this press release and oral statements made
by the Company constitute forward-looking statements concerning the
Company's business and products. These statements include, without
limitation, statements regarding our ability to prepare the Company
for growth, the Company's planned capacity expansion and
predictions and guidance relating to the Company's future financial
performance. We have based these forward- looking statements
largely on our current expectations and projections about future
events and financial trends that we believe may affect our
financial condition, results of operations, business strategy and
financial needs, but they involve risks and uncertainties that
could cause actual results to differ materially from those in the
forward-looking statements, which may include, but are not limited
to, such factors as unanticipated changes in product demand
especially in the pharmaceutical industry, pricing and demand
trends for the Company's products, changes to government
regulations, risk associated with operation of the Company's new
facilities, risk associated with large-scale implementation of the
Company's business plan, the ability to attract new customers,
ability to increase its product's applications, cost of raw
materials, downturns in the Chinese economy, and other information
detailed from time to time in the Company's filings and future
filings with the United States Securities and Exchange Commission.
Investors are urged to consider these factors carefully in
evaluating the forward-looking statements herein and are cautioned
not to place undue reliance on such forward-looking statements,
which are qualified in their entirety by this cautionary statement.
The forward-looking statements made herein speak only as of the
date of this press release and the Company undertakes no duty to
update any forward-looking statement to conform the statement to
actual results or changes in the Company's expectations. For more
information, please contact: Shengtai Pharmaceutical, Inc. Ms. Yiru
Melody Shi Chief Financial Officer Tel: +1-949-468-7078 Email:
Shengtai Pharmaceutical, Inc. Haining Michelle Wang Investor
Relations Manger Tel: +86-536-6295802 Email: DATASOURCE: Shengtai
Pharmaceutical, Inc. CONTACT: Rebecca Alexander, +1-914-613-3648,
+86-10-5913-7998, Web site: http://www.shengtaipharmaceutical.com/
Copyright